ClinicalTrials.gg
RecruitingNCT05945576IDMetUpdated Feb 12, 2026

IDMet (RaDiCo Cohort) (RaDiCo-IDMet)

An observational study in Silver Russell Syndrome, Beckwith-Wiedemann Syndrome and Transient Neonatal Diabetes Mellitus, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 20 sites in France. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational

How we know

From the registry’s dates

  • Started Mar 2017; still recruiting 9 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
2,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Angelman Syndrome with a site in France — 3 open to participants now, 4 under way, none of them phase 3. Angelman Syndrome · France.

Started
2017
the only one that year
Observational
4 of 10
3 open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
Institut National de la Santé Et de la Recherche Médicale, France

Among the 10 studies in Angelman Syndrome with a site in France, this one is the only one that started in 2017, is one of 4 observational ones, and was the 7th registered.

Angelman Syndrome

52 studies on the registry are indexed under Angelman Syndrome; 16 are open to participants now.

Browse Angelman Syndrome studies →

Open to participants now

3 of the 10 studies in Angelman Syndrome with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 14 Angelman Syndrome studies recruiting now, 6 (43%) set no upper age limit and 7 (50%) stop at 75 or younger; 14 take children under 18; none take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Angelman Syndrome with a site in France, or all of them as a file.
02

Study summary

The goal of this observational study is to describe the natural history of imprinting disorders (IDs) according to their metabolic profile in all patients (adults and children) affected with an ID regardless of the severity of the disease, with a molecular characterization, with a signed informed consent for all subjects, followed in one partner's center.

The main questions it aims to answer are:

  • Can we identify common metabolic profiles for all imprinted diseases?
  • Which imprinting disorders have an impact on the metabolic profiles of IDs?
  • Which are the metabolic risks associated to IDs?
  • Can we use the metabolic profiles for the clinical classification and prognosis of IDs?
  • Are there common therapeutic approaches for all IDs?
03

Conditions studied

  • Silver Russell Syndrome
  • Beckwith-Wiedemann Syndrome
  • Transient Neonatal Diabetes Mellitus
  • Angelman Syndrome
  • Prader-Willi Syndrome
  • Temple Syndrome
  • Kagami-Ogata Syndrome
  • Pseudohypoparathyroidism
  • Familial Precocious Puberty
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients (adults and children) affected with an ID regardless of the severity of the disease, with a molecular characterization, with a signed informed consent for all subjects, followed in one partner's center.

Eligibility criteria

Inclusion Criteria:

  • Patients (adults and children) affected with an ID regardless of the severity of the disease
  • A confirmed diagnosis of ID (based on molecular diagnosis)
  • A signed for adults or signed informed consent of parents/guardians of minors/ protected adult.

Non-Inclusion Criteria:

There are no non-inclusion criteria.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. The clinical characteristics of IDs in pediatric and adult's patients.

    Time frame: Through study completion, an average of 10 years

  2. The genetic characteristics of IDs in pediatric and adult's patients.

    Time frame: Through study completion, an average of 10 years

  3. The biological characteristics of IDs in pediatric and adult's patients.

    Time frame: Through study completion, an average of 10 years

  4. The morphometric characteristics of IDs in pediatric and adult's patients.

    Time frame: Through study completion, an average of 10 years

Secondary outcomes

  1. Search for an association between the metabolic phenotype of IDs patients' and their biological profil.

    Time frame: At the time of diagnosis (or at first measurement)

  2. Determination of the prevalence of metabolic abnormalities (MA).

    Time frame: At inclusion

  3. Estimation of the risk for metabolic complications such as obesity, diabetes, cardiovascular disease (CVD), metabolic syndrome.

    Time frame: 10 years after

  4. Description of different therapeutic approaches and identification of a common base for all IDs.

    Time frame: Through study completion, an average of 10 years

  5. Variations of quality-of-life scores.

    Time frame: Through study completion, an average of 10 years

  6. Analyse of (epi)genetic mutations transmission in proband and relatives.

    Time frame: Through study completion, an average of 10 years

Other outcomes

  1. Identification of different metabolic profile which allow a clinical classification of IDs.

    Time frame: Through study completion, an average of 10 years

  2. Description and identification of the most relevant biological and clinical practices for diagnostic and follow-up of ID patients.

    Time frame: Through study completion, an average of 10 years

  3. Identification of a group of French patients with the same characteristics.

    Time frame: At inclusion

  4. Search of an association between blood metabolic markers, genetic pattern and gut microbiota.

    Time frame: Through study completion, an average of 10 years

  5. Description of different scientific rational for transferring a therapeutic approach (clinical guidelines) from an ID to another (identification of common phenotype, i.e. metabolic profile).

    Time frame: Through study completion, an average of 10 years

07

Study locations

8 of 20 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2017 (actual). Primary completion is estimated for Mar 2028, 132 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2023
First posted
Jul 14, 2023
StartActual
Mar 10, 2017
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05945576
Responsible party
Sponsor
First posted
Jul 14, 2023
Start date
Mar 10, 2017
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Feb 12, 2026

Study contacts

Agnès LINGLART
Contact
agnes.linglart@aphp.fr
+33 1 45 21 78 53
Irène NETCHINE
Contact
irene.netchine@aphp.fr
Agnès LINGLART
principal investigator · Inserm U1169

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion